ID   WM1361A
AC   CVCL_6788
SY   WM-1361A; WM 1361A; WC00075; EST69
DR   BioGRID_ORCS_Cell_line; 1751
DR   cancercelllines; CVCL_6788
DR   Coriell; WC00075
DR   Cosmic; 686402
DR   Cosmic; 1047649
DR   Cosmic; 1155284
DR   Cosmic; 1155540
DR   Cosmic; 1303063
DR   Cosmic; 1507599
DR   Cosmic; 1669263
DR   Cosmic; 2163799
DR   Cosmic; 2233686
DR   ESTDAB; ESTDAB-069
DR   GEO; GSM109025
DR   GEO; GSM156022
DR   GEO; GSM185174
DR   GEO; GSM185175
DR   GEO; GSM185176
DR   GEO; GSM185177
DR   GEO; GSM952593
DR   IARC_TP53; 26076
DR   Progenetix; CVCL_6788
DR   Rockland; WM1361A-01-0001
DR   Wikidata; Q54994168
RX   PubMed=2068080;
RX   PubMed=2253310;
RX   PubMed=16827748;
RX   PubMed=17260012;
RX   PubMed=18632627;
RX   PubMed=19340423;
RX   PubMed=23851445;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; Wistar).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445; Wistar).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: Coriell; WC00075; probable.
ST   Source(s): ESTDAB=ESTDAB-069; Wistar
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 30,31.2
ST   D2S1338: 25
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 8,10
ST   D8S1179: 12,13
ST   FGA: 22,25
ST   TH01: 7 (Wistar)
ST   TH01: 7,8 (ESTDAB=ESTDAB-069)
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_6993 ! WM1361B
OI   CVCL_6994 ! WM1361C
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 28
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//